We have characterized the promoter of the mouse retinoic acid receptor a2 (mRAR-a2) isoform. This promoter contains a retinoic acid response element (RARE) that closely resembles the RARE that is present in the RAR-f82 promoter. Moreover, RAR-a2 and RAR-fl2 proximal promoter sequences are similar to each other and generate transcripts whose respective start sites are located at similar positions. The RAR-a2 RARE consists of two directly repeated 5'-GTTCA-3' motifs to which all three RARs (a, (3, and y) bind in vitro.
The highly pleiotropic effects of retinoic acid (RA), a major developmental signaling molecule, are mediated by the products of three nuclear receptor genes (RAR-a, -(3, and -y), which interact with cis-acting RA response elements (RAREs) present in the promoter ofRA target genes, thereby modulating their transcription (refs. 1 and 2 and references therein). Each subtype gene encodes several isoforms that are generated by alternative splicing of primary transcripts initiated from either one of two promoters. A previous report (3) showed that the mRNA level of RAR-a2, one of the two major RAR-a isoforms, is markedly increased in murine F9 and P19 embryonal carcinoma (EC) cells upon RA treatment. We have now characterized the promoter that generates this isoform and demonstrate here that it contains a RARE.t
MATERIALS AND METHODS
Mapping of the Mouse mRAR-a2 (mRAR-a2) Transcription Start Site. A 1.4-kilobase (kb) EcoRI-Xho I fragment derived from phage AG3 mRAR-a (3) was subcloned into the pBluescript SKII(+) vector (Stratagene) to yield the recombinant pEX, of which the 1.3-kb Xba I-Xho I segment was sequenced (Fig. 1A) . The location of the mRAR-a2 start site was determined as described (4) by primer extension using the 5'-end-labeled antisense primer OY113 (Fig. 1A) and total RNA isolated from RA-treated (1 ,uM) P19 EC cells (Fig. 1B) .
Reporter Genes for mRAR-a2 Promoter Activity. The Xba I-Xho I mRAR-a genomic DNA fragment was inserted in the Xba I and Xho I sites of the chloramphenicol acetyltransferase (CAT) reporter plasmid pBLCAT3 (6) . The pBLCAT3 polylinker Pst I and Sph I sites were eliminated by digestion with HindIII and Xba I, followed by blunt-end ligation, which restored an Xba I site and yielded RAR-a2/CAT1 containing unique Pst I and Sph I sites ( Fig. 2A) . RAR-a2/CAT1 was digested with Pst I and Xho I, and the DNA ends were filled-in, yielding RAR-a2/CAT2 after ligation. RAR-a2/ CAT3 and RAR-a2/CAT4 were obtained by inserting the 549-bp Pst I-Xho I fragment and the 859-bp Sph I-Xho I fragment of pEX into the corresponding sites of pBLCAT3 ( Fig. 2A) . RAR-a2ml/CAT1 was engineered from RAR-a2/ CAT1 by introducing six transversions into the a2 RARE through PCR-assisted site-specific mutagenesis with four primers. The sequence of the two complementary "central" mutant primers corresponded to that of the a2 RARE ml oligonucleotide (Fig. 3A) . The two "external" primers were as follows: sense 5' primer, 5'-GGACACC CAATICTG-CATTCGTG-3'; antisense 3' primer, 5'-ATCCCCTGCAGL-GAAGATGCAGCGGC-3' (nucleotides -258 to -234 and nucleotides +48 to +72, respectively; see Fig. 1A ; the unique Sph I and Pst I restriction sites are underlined). PCR reactions were as described (7) and the final PCR product was digested with Sph I and Pst I. This mutated Sph I-Pst I cassette (Fig. 1A , -245 to +66) was exchanged with the corresponding Sph I-Pst I fragment of RAR-a2/CAT1 to yield RAR-a2ml/CAT1. a2RARE/tk-CAT, a2RAREml/tk-CAT, a2RAREm2/tk-CAT, and a2RAREm3/tk-CAT were constructed by inserting the synthetic oligonucleotides a2 RARE, a2 RARE ml, a2 RARE m2, and a2 RARE m3 between the HindIII and Xba I restriction sites of pBLCAT8+ (8) . Other materials and methods were as described previously (9, 10) .
RESULTS
Isolation of the mRAR-a2 5' Flanking Region and Mapping of the Start Site of mRAR-a2 Transcripts. The 18-kb genomic DNA insert of clone AG3 mRAR-a contains a single Xho I restriction site, which is also present in the 5' UTR of the mRAR-a2 cDNA isoform (3) . The sequence of a 1323-bp Xba I-Xho I fragment that hybridized to mRAR-a2-specific cDNA sequences was determined (Fig. 1A) . As expected, its 3' extremity overlaps with the 5' UTR of the cloned mRAR-a2 cDNA sequence. The more-upstream genomic sequences contain recognition sites for rare-cutting restriction enzymes generally associated with CpG islands in mammalian genomes (ref. 11 and references therein), which suggests that this region contains the RAR-a2 start site.
The 5' end of exon E3, which encodes the A region and the entire 5' UTR of mRAR-a2 (3), was determined by PCR analysis of mRAR-a2 transcripts and primer extension. PCR was carried out with cDNA generated by reverse transcription [using the mRAR-a2 5'-UTR-specific antisense primer 5'-AAGTTGTGCAGGTTGGAGGA-3' (3)] from poly(A)+ RNA of RA-treated P19 EC cells and one of five oligonucleotide primers (Fig. 1A , arrows 1-5) together with a common 3' primer (arrow 6). In all five cases, a specific PCR product of the expected size was detected (data not shown), indicating that the 5' border of exon E3 was located upstream from Abbreviations: UTR, untranslated region; RA, retinoic acid; RAR, RA receptor; mRAR, mouse RAR; hRAR, human RAR; RARE, RA response element; CAT, chloramphenicol acetyltransferase; tk, thymidine kinase; EC, embryonal carcinoma. *To whom reprint requests should be addressed.
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mRAR-a2 and mRAR-(82 Proximal Promoter Sequences Are Similar. The mRAR-a2 5' region contains several putative binding sites for the transcription factor Spl (boxed in Fig. 1A ), located in either the 5' UTR or the proximal promoter sequences. No obvious TATA-or CCAAT-box sequences were noticed. However, a sequence closely resembling the RARE previously characterized in the mouse and human RAR-,B2 promoters (12, 13) lies upstream of the cap site ( Fig. 1 A and C, nucleotides -54 to -39). This putative RARE consists of a direct repeat of 5'-GTTCA-3' with a 6-nucleotide spacer whose sequence differs from that of the 132 RARE. Interestingly, this presumptive RARE is located at a position (with respect to the cap site) that is similar to that of (2 RARE. A comparison between the mRAR-a2 and mRAR-,B2 (5) proximal promoter sequences reveals that the two sequences are closely related (Fig. 1C) . The sequence 5'-ATTAG-GCAA-3' located 10 bp downstream ofthe putative a2 RARE is identical to a sequence located at an equivalent position in the mRAR-,32 promoter (black bar in Fig. 1C ), where it partially overlaps the RAR-/2 TATA box (5, 12, 13) . This observation, and the fact that RAR-a2 and RAR-,82 start sites are located at the same position within their respective genomic DNA sequences (13) , suggests that this sequence, which is conserved in the hRAR-a2 promoter (see Fig. 1C 2) . A similar construct containing the mRAR-/32 promoter (RAR-/82/CAT; lanes 5 and 6) and RAR-a2ml/CAT1, which carries a mutated RARE (lanes 7 and 8; see a2 RARE ml sequence in Fig. 3A) , were similarly assayed. are also present in P19 cells (P. Kastner and P.C., unpublished observation), could be involved in this induction is unlikely, since a response was seen with as little as 0.1 nM RA (Fig. 2C) , a concentration at which RXRs do not respond (17 To prove that the above putative RARE (Fig. 1 A and C) was responsible for RA induction, the activity of the mutant RAR-a2ml/CAT1 (Materials and Methods) was tested in transfection experiments (Fig. 2B, lanes 7 and 8) . Whereas its basal activity (i.e., in the absence of RA) was unchanged (compare lanes 3 and 7), its RA inducibility was virtually abolished (compare lanes 4 and 8) .
The function of the a2 RARE was further investigated by inserting the directly repeated 5'-GTTCA-3' motifs (Fig. 3A) upstream of the herpes simplex virus tk promoter, yielding a2RARE/tk-CAT. The plasmids a2RAREml/tk-CAT, a2RAREm2/tk-CAT, and a2RAREm3/tk-CAT were similarly constructed using the a2 RARE mutants ml-m3 (Fig.  3A) . These reporter genes were transfected into P19 cells either alone or together with either the parental expression vector pSG5, as a control (18), or pSG5, expressing either mRAR-al, -,/2, or -yl (3, 5, 16, and 19) . ,82RARE/tk-CAT, which contains the human 132 RARE (13) inserted upstream of the tk promoter of pBLCAT8+, was used for comparison. a2RARE/tk-CAT was RA-inducible, albeit to a lesser extent than 832RARE/tk-CAT (about one-third as efficiently, as determined by radioactivity counting; Fig. 3B, lanes 1-6) , suggesting that the a2 RARE may have a lower affinity than the /82 RARE for RARs (see below). The magnitude of the induction was increased upon cotransfection with mRAR-al, -,82, or -yl expression vectors (Fig. 3B, lanes 7-12 , and data not shown). In contrast, no RA induction was observed with the a2 RARE mutants ml-m3 (Fig. 3B, lanes 13-18) .
Binding of RAR-a, -13, and -y to the mRAR-a2 RARE in Vitro. Binding of RARs to a2 RARE was investigated in vitro, using a gel retardation/shift DNA-binding assay and nuclear extracts prepared from COS-1 monkey cells transiently transfected with vectors expressing either hRAR-al, -/32, or -yl. Specific retarded complexes (arrow 1 in Fig. 4A ) were observed when a 32P-end-labeled a2 RARE probe was incubated with COS-1 extracts containing any one of the three hRARs. These complexes were not observed with the mutant Proc. Natl. Acad. Sci. USA 88 (1991) 10141 oligonucleotides (probe, 10 fmol, 50,000 cpm) corresponding to the wild-type a2 RARE (lanes 1-7) , the mutated a2 RARE ml (lanes [8] [9] [10] [11] [12] [13] [14] , or the wild-type ,B2 RARE (lanes [15] [16] [17] [18] [19] were incubated with 4 ,ug of total protein extract from COS-1 cells transfected with one of the three hRAR subtypes (al, 82, or l4; see ref. 9 ) or pSG5 (0), as indicated. Arrows 1 and 2 point to complexes corresponding to specific RARE/RAR interactions in the absence (-) or presence (+) of RAR antibodies specific for either RAR-a, -B, or --y (antiserum), respectively (see ref. 9). (B) Lower affinity of RAR for a2 RARE than for /2 RARE. Extracts of COS-1 cells transfected with hRAR-al were incubated with 32P-end-labeled probes corresponding to either the a2 or the /32 RARE, as indicated, and increasing amounts of nonradioactive ("cold") competitor RARE. Incubations corresponding to lanes 1, 6, 11, and 16 contained no competitors (-); competitors were added as follows: 10 fmol for lanes 2, 7, 12, and 17; 30 fmol for lanes 3, 8, 13, and 18; 100 fmol for lanes 4, 9, 14, and 19; 300 fmol for lanes 5, 10, 15, and 20. a2 RARE ml, or with extracts prepared from pSG5 (18)-transfected cells (Fig. 4A, lanes 1-14) . The specificity ofthese complexes was further demonstrated by using a "supershift" assay (10) in which antibodies specific for each RAR subtype were added. In each case a supershifted complex was observed, indicating specific binding of hRARs to a2 RARE (arrow 2). Specific complexes were seen with a control 32P-end-labeled /2 RARE oligonucleotide, as expected (lanes [15] [16] [17] [18] [19] .
RAR Binding to a 2 RARE Is Weaker Than That to fi2 RARE. The observation that the magnitude ofRA inducibility of a2RARE/tk-CAT is less than that of /2RARE/tk-CAT (see above) suggested that RARs may bind to a2 RARE with a lower affinity than to /32 RARE. Competition experiments were performed with a2 RARE and /32 RARE oligonucleotides (used either as radiolabeled probes or as nonradioactive competitors) and cell extracts prepared from COS-1 cells transfected with hRAR-al. Although both a2 RARE and /32 RARE probes had similar specific activities, a smaller amount of specific complex was formed with the a2 RARE than with the 82 RARE oligonucleotide (arrow in Fig. 4B,  compare lanes 1 or 6 with lanes 11 or 16) . Moreover, a nonradioactive a2 RARE oligonucleotide was about onethird as efficient as the corresponding /32 RARE oligonucleotide at competing with either labeled a2 RARE or /32 RARE probe for binding to hRAR-al (Fig. 4B, compare lanes 1-5  with lanes 6-10, and lanes 11-15 with lanes 16-20) . Competition experiments conducted with extracts prepared from COS-1 cells transfected with vectors expressing either hRAR-/32 or hRAR-yl yielded similar results (not shown).
DISCUSSION
A previous paper (3) reported the existence of two major mouse RAR-a isoforms, mRAR-al and -a2, and observed that the level of mRAR-a2 transcripts, but not that of mRAR-al, was increased upon RA treatment of P19 and F9 EC cells (3) . Moreover, mRAR-al is ubiquitously expressed, whereas mRAR-a2 distribution is more restricted (3). It was also found that the human and mouse RAR-al promoters resemble those of "housekeeping" genes (3, 20) . We show here that the RA-induced accumulation of mRAR-a2 transcript is mediated through an alternative RAR-a promoter that contains a RARE.
The present sequencing data extend those published previously ( There is no consensus TATA box 30 bp upstream from the mRAR-a2 (and hRAR-a2) start site, but an A+T-rich sequence is present at this position. It may correspond to a degenerate TATA box, in view of its conservation in the hRAR-a2 promoter and in the highly similar RAR-/32 promoter (see below and Fig. 1C ). There are several putative binding sites for the Spl factor (21) in the mRAR-a2 5' region (Fig. 1A) . Whether they contribute to the basal activity of the RAR-a2 promoter remains to be investigated.
The most interesting feature of the mRAR-a2 proximal promoter sequence is the presence of a RARE consisting of the directly repeated motif, 5'-GTTCA-3', with 6 intervening bases. The role of these motifs in mediating the RA response is demonstrated by the detrimental effect of their mutation on RA inducibility ofreporter genes containing either the natural mRAR-a2 promoter (Fig. 2B) or the heterologous tk promoter (Fig. 3) . Furthermore, our in vitro studies demonstrate that all three RARs bind specifically to the a2 RARE (Fig.  4A) . The mouse a2 RARE, whose sequence and location are conserved in the hRAR-a2 5' flanking region, is strikingly similar to that of the human (13) and mouse (12) /2 RAREs, in both sequence and location (Fig. 1C) . However, the /32 RARE is -3-fold more efficient than its a2 counterpart for both RA inducibility in vivo (Fig. 3B) and RAR binding in vitro (Fig. 4B) , which further supports the conclusion that these RAREs mediate RA-dependent transcriptional induction.
The above results indicate that the spacer sequence located between the GTTCA repeated motifs and/or the bases flanking these motifs must modulate RARE "strength. are required to define precisely the contribution of each base of this consensus sequence to RARE strength. An additional GGTCA motif located further upstream of the RARE is present in both the RAR-a2 and RAR-/82 promoters (see Fig.  1 A and C). Whether this single motif cooperates with the RARE to mediate RA inducibility is unknown. Interestingly, this motif is contained within the sequence 5'-TGGG-TGGGTCA-3', which is conserved in the mRAR-,82 promoter (see Fig. 1 ) and is also present in the proximal region of the ovalbumin gene promoter, where it has been shown to be a weak estrogen response element (24) and also to mediate the activity of the transcription factor AP-1 (25) . Previous reports (1) (2) (3) 5) have stressed similarities in the overall structural organization of the three RAR genes, as well as similarities between the amino acid sequences of the N-terminal A regions of the isoforms transcribed from the upstream P1 promoters (al, ,31/,33, and 'yl), on the one hand, and of those transcribed from the downstream P2 promoters (a2, 832, and 'y2) on the other (1, 2). Our present results support the idea that the RAR-a2 and RAR-,82 transcription units were derived by duplication of a common ancestor. However, the RAR-y2 isoform is not RA-inducible (16) , which suggests that it originated from a duplication event that preceded the RAR-a/,8 duplication. Thus the primordial RAR gene may have had two promoters, a RA-noninducible upstream promoter (P1) and a RA-inducible downstream promoter (P2), and the inducibility of the RAR-y2 P2 promoter would have been lost. In any event, the question arises as to which RAR subtypes and isoforms can mediate the RA induction of the a2 promoter. All three RARs can bind to the mRAR-a2 RARE in vitro and transactivate a2RARE/tk-CAT reporter genes in cultured cells. It remains to be seen whether these RAR properties hold true under "natural" conditions within the context of the RAR-a2 promoter, and in cells and tissues where the expression of the isoform is controlled by RA during development and in adult vertebrates.
